This story has been updated from a previous version to include information about the platorms on which Cepheid's test can be run.
NEW YORK – The US Food and Drug Administration on Friday issued Emergency Use Authorization for Cepheid's Xpert Xpress SARS-CoV-2 test for diagnosing COVID-19.
It is the first EUA for a SARS-CoV-2 that can be used at the point of care. In addition to high- and moderate-complexity laboratories, the rapid molecular test can be used in certain patient-care settings, the agency said.